Rocky Mountain Oncology Society

During a live event, Matthew Lunning, DO, discussed key factors that determine whether patients should receive CAR T-cell therapy, autologous stem cell therapy, or other treatment options.

During an in-person Community Case Forum in partnership with the Rocky Mountain Oncology Society, Mei Wei, MD, discussed data from the TROPiCS-02 trial of sacituzumab govitecan in patients with metastatic breast cancer.

David J. Andorsky, MD, discussed real-world findings from a study which evaluated BTK inhibitors in adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

If the title is correct, an article in the November 10 issue of the Journal of Clinical Oncology shows that many randomized trials in oncology are improperly designed and many drugs used in oncology have been approved based on the wrong end point.

Join the Rocky Mountain Oncology Society for an exciting evening of learning and networking at our Professional Development Workshop.